- Survival with anti-PD1/PDL1 immunotherapy [ Time Frame: 12 weeks ]
Overall survival from treatment with anti-PD1/PDL1 immunotherapy
- Duration of treatment [ Time Frame: 12 weeks ]
Duration of treatment with PD1/PDL1 immunotherapy
- Survival [ Time Frame: 12 weeks ]
Overall survival from the start of the first treatment
- Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by previous immunotherapy [ Time Frame: 12 weeks ]
Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by following data: which immunotherapy, date of treatment beginning/end
- Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by adverse event [ Time Frame: 12 weeks ]
Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by following data: numbers of treatment related adverse events from CTCAE v4.0
- Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by remarkable event [ Time Frame: 12 weeks ]
Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by following data: date of best response, date of progression, date of death)
- To identify factors predictive of treatment response by immunotherapy in responder patients [ Time Frame: 12 weeks ]
Identify factors predictive of treatment response by immunotherapy in responder patients by collecting following data: Demographics data, treatment data, and blood test results and histological data
- To identify factors predictive of the response of immunotherapy treatment of progressive patients [ Time Frame: 12 weeks ]
Identify factors predictive of treatment response by immunotherapy of progressive by collecting following data: Demographics data, treatment data, and blood test results and histological data
- To identify factors predictive of the response of immunotherapy treatment of all patients [ Time Frame: 12 weeks ]
Identify factors predictive of treatment response by immunotherapy of all patients by collecting following data: Demographics data, treatment data, and blood test results and histological data
- To identify factors predictive of the response of immunotherapy treatment according to follow-up treatment [ Time Frame: 12 weeks ]
Identify factors predictive of treatment response by immunotherapy according to type of treatment after PD1/PDL1 immunotherapy